Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs
Sapience Therapeutics has raised $2.0M in total funding. The most recent round was Grant. The last funding was announced in May 2023.
Sapience Therapeutics's investors include Bristol-Myers Squibb, Connectivity Ventures Fund, Kingdon Capital, National Institute of Allergy and Infectious Diseases, Celgene.
Sapience Therapeutics is headquartered in Scarsdale, United States.
Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs
Sapience Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sapience Therapeutics — Funding & Investors." VCBacked, May 4, 2023, https://www.vcbacked.co/company/sapience-therapeutics. Accessed November 17, 2026.
VCBacked. (2023). Sapience Therapeutics — Funding & Investors. Retrieved November 17, 2026, from https://www.vcbacked.co/company/sapience-therapeutics
{{cite web |title=Sapience Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sapience-therapeutics |website=VCBacked |access-date=November 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Sapience Therapeutics? Request a listing update